Literature DB >> 32549983

The use of exhaled nitric oxide and peak expiratory flow to demonstrate improved breathability and antimicrobial properties of novel face mask made with sustainable filter paper and Folium Plectranthii amboinicii oil: additional option for mask shortage during COVID-19 pandemic.

Sy Duong-Quy1,2,3, Xuan Ngo-Minh3, Trinh Tang-Le-Quynh1, Tram Tang-Thi-Thao1, Bao Nguyen-Quoc1, Khiet Le-Quang1, Dinh Tran-Thanh1, Nhu Doan-Thi-Quynh1, Ethan Canty2, Toan Do2, Timothy Craig2.   

Abstract

BACKGROUND: Medical face masks are integral personal protective equipment against infectious airborne disease and become scarce during epidemic outbreaks such as COVID-19. A novel, sustainably manufactured face mask with antimicrobial and anti-inflammatory properties from oil of Folium Plectranthii amboinicii can be an effective alternative to internationally sold masks.
METHODS: This prospective, randomized study assigned subjects (n=67) to either conventional surgical face mask or Lamdong Medical College (LMC) face mask for three hours. Fractional concentration of nitric oxide in exhaled breath (FENO) and peak expiratory flow (PEF) was measured before and after mask use. Subjective reporting on respiratory symptoms was also analyzed. Masks were then incubated and analyzed for microorganism growth.
RESULTS: Subjects assigned the LMC mask had a lowered FENO (p<0.05) compared to conventional face masks after mask wearing. Subjects with LMC mask use reported higher comfortability (p<0.05), breathability (p<0.05), and lower allergy symptoms (p<0.05). The LMC mask has visually less microorganism growth in the cultured medium, measured by sterile ring radius.
CONCLUSIONS: The LMC face mask is a renewably manufactured personal protective tool with antibacterial capacity that can serve as an effective alternative to internationally sold surgical face mask during shortage of mask due to COVID-19. ©Copyright: the Author(s).

Entities:  

Keywords:  COVID-19; Filter paper mask; Folium Plectranthii amboinicii; mask shortage; pandemic

Year:  2020        PMID: 32549983      PMCID: PMC7282423          DOI: 10.4081/mrm.2020.664

Source DB:  PubMed          Journal:  Multidiscip Respir Med        ISSN: 1828-695X


Introduction

Medical face masks are commonly used in the prevention of infectious airborne diseases [1-3]. In epidemic outbreaks, such as COVID-19 pandemic, the scarcity of surgical masks presents a serious public health challenge to preventing transmission of infectious diseases in the healthcare environment [4]. China, which produced roughly 50% of the global supply of face masks, was also the epicenter of the COVID-19 outbreak. As the key supplier of face masks, this created a significant shortage throughout the world [4]. Furthermore, the increased demand for face masks caused extreme price hikes, which severely deterred people from purchasing them. This occurred even in countries not experiencing an outbreak of COVID-19. It is crucial for countries to have alternative means to produce effective, high quality face masks during an epidemic without needing to rely on the international supply of mask manufacturing resources. Face masks are generally made of non-renewable materials, such as plastic-based products, increasing global carbon emission and pollution. During infectious disease outbreaks, such as the 2019 outbreak of COVID-19, increased demand for plastic-based face masks also places a significant burden on the environment. Therefore, developing and manufacturing a face mask using sustainable materials, like filter paper, would be cleaner and safer for the environment. The masks have the potential to be manufactured in more countries, in a sustainable manner, which would improve the supply during epidemics while also reducing the impact of plastics in the environment. Folium Plectranthii amboinicii (Lour.) Speng (Lamiaceae), (syn. Colius ambionicus), or Mexican Mint oil, is a traditional Vietnamese medicinal plant commonly used to treat upper respiratory infections, bronchitis, and gastrointestinal infections [5-8]. Previous studies have demonstrated that the Plectranthii amboinicii leaf oil possesses antimicrobial and antioxidant properties [9-11]. The oil has antibacterial effects against Staphylococcus aureus, Escherichia coli and Bacillus subtilis and antifungal effect against Candida albicans [6,11]. However, other uses of the oil have not been explored or tested. At high concentration, the oil demonstrated antioxidant properties similar to butyl hydroxyl toluene (BTH) [6]. In many countries, Plectranthii amboinicii’s antimicrobial property is used to treat respiratory tract infections and gastroenterological illnesses and its antioxidant property is applied as a pain-killer and anti-anxiety agent [5-7]. The anti-inflammatory and antimicrobial properties of Plectranthii amboinicii leaf oil have not been explored in personal protective gear such as surgical face masks. However, the use of face mask infiltrated with the compound of antimicrobial property must be checked to assure its safety for users. Therefore, the comfortability with breathing and other respiratory side effects of the novel face mask after having worn it should be clarified by using the relevant and compatible tools. Fractional concentration of nitric oxide in exhaled breath (FENO), a relevant inflammatory biomarker of respiratory system, has been used to measure the response of airways with allergens and other stimulants in breathing air [12]. Currently, FENO is used largely in monitoring patients with asthma and airway hyperresponsiveness [13,14]. In these patients, the measurement of peak expiratory flow (PEF) is also recommended to evaluate the immediate progression of airway obstruction via the use of peak flow meter [15]. The aim of this study is to determine if a novel face mask, manufactured from locally-sourced, sustainable materials with antimicrobial and anti-inflammatory properties from the Plectranthii amboinicii plant oil, can serve as an effective alternative to current surgical face masks sold on the international market. In the present study, the comfortability and other side effects of the novel face mask after wearing were demonstrated by clinical symptoms, FENO, and PEF measurements.

Materials and Methods

Materials

The Lamdong Medical College (LMC) mask is made from qualified cellulose paper with four filter paper (two in external face [1st and 2nd layers] or front layers and two in internal face [6th and 7th layers] or back layers) and two blotter papers [3rd and 5th layers] placed in the middle separated by one layer of water proof paper [4th layer] (Figure 1). The 3rd and 5th blotter paper layers are placed in external face which contains activated carbon, standardized BSI (Benzoic acid, Salicylic, and lode) solution of 5%, and Plectranthii amboinicii plant oil extract of 0.5%. In total, the LMC mask is made up of four layers of filter paper, two layers of blotter papers, and one layer of water proof paper (Figure 1). This mask has been qualified by the criteria of Directorate for Standards, Metrology and Quality of Vietnam. The conventional face mask used to compare the LMC mask is a four-layer activated carbon surgical mask.
Figure 1.

Detail structure of LMC face mask. LMC, Lamdong Medical College.

Detail structure of LMC face mask. LMC, Lamdong Medical College.

Study subjects

The staff of local administrative colleges (Dalat, Vietnam) was eligible for this study after signing an Institutional Review Board- Approved consent form. The study was approved by the Ethic Council of Lamdong Medical (LMC2020.01.SRS, 15th January 2020). Subjects were informed that they could withdraw at any stage of the study.

Inclusion criteria

To be eligible for the study, subjects needed to be healthy, consenting adults (≥18 years), without upper or lower respiratory acute symptoms or chronic diseases such as allergic rhinitis, rhinosinusitis, chronic bronchitis, asthma or chronic obstructive pulmonary disease (COPD).

Exclusion criteria

Adults with one of the following criteria were excluded from this study: active smoking; having respiratory symptoms (rhinorrhea, cough, respiratory difficulty, allergy, etc.); known respiratory allergy, smoker, alcohol drinker, or ingested caffeine the day of study; unable to perform exhaled nitric oxide (NO) and peak flow measurements; or being unable to obtain consent or absent during followup.

Study design

This was a prospective and randomized clinical study. After consenting to the study and providing demographic data, peak flow and exhaled NO measurements were obtained from each subject at inclusion. Subjects were then randomized to wear either the LMC mask or the conventional mask (GreetMed, ANJ International Corp., UK) with the same administrative activities. Subjects were asked subjective reporting on comfortability and symptoms of their assigned masks. Subjects remained in the same facility for three hours wearing their assigned masks and then repeated peak flow and exhaled NO measurements once the three hours were complete. In this duration, symptoms of discomfort, cough, allergic symptoms, rhinorrhea, or respiratory distress were continuously monitored. The masks of each subject were then collected for laboratory analysis. For each mask, the front and back layer of the mask were collected, trimmed, and cut into three pieces, yielding a total of six pieces. One piece from the front and back layer were separated into plate count agars. Each plate was placed into an incubator at 37°C for 24 h and bacterial growth was compared.

Peak expiratory flow

PEF was done by Peak - Flow Eolys (AstraZeneca, France) according to the manufacturer’s instructions. Subjects were asked to provide three PEF measurements, and the highest value among the three measurements was used for data analysis.

Exhaled nitric oxide measurements

Fractional concentration of NO in exhaled breath (FENO) was done by NObreath (Bedfront Scientis Ltd, Kent, England) according to manufacturer’s instructions with expiratory air flows of 50 mL/second for FENO. The FENO was determined by measuring the room’s FENO level and subtracting this value from the subject’s measured FENO value. The use of portable device for FENO measurement was done as recommended previously [12]. The mean value of two correctly performed measures was used for analyses. FENO levels were classified as recommended by the American Thoracic Society for adult (<25 ppb: normal; 25-50 ppb: increased; >50 ppb: highly increased) [13].

Subjective symptoms

Subjects were asked subjective symptoms about the comfort of the mask they wore, symptoms of rhinorrhea, cough, allergic symptoms, or respiratory distress. These symptoms were monitored continuously while the subjects were wearing the masks.

Biological activity testing

Sabouraud dextrose, and MacConkey agars were used to assess bacterial growth of each face mask (LMC mask and conventional mask) before use and after use. Each agar was placed into an incubator set to 37°C for 24 h. After the 24 h, bacterial growth was compared for each piece using visual and diameter measurements of growth.

Statistical analysis

SPSS software 16.0 (Chicago, IL, USA) and Microsoft Excel were used to perform statistical analysis on all recorded data. Mean±SD was used to present categorical variables. T-test and ANOVA were used to differentiate between groups. Differences were significant at p<0.05 level and confidence interval ≥95%.

Results

Demographic and functional characteristics of study subjects

From January 25th to March 25th, 2020, 67 adults who met the inclusion criteria were included in the study. The subjects were 32.8% males, had a mean age of 39.4±10.2 years, mean height of 159.6±6.9 cm, mean weight of 56.8±7.7 kg, and mean BMI of 26.4±2.9 kg/m[2] (Table 1). The 67 study subjects were randomized into two groups (Group 1 with n=34, and Group 2 with n=33) with no significant demographic differences (p>0.05) between the groups (Table 2). Group 1 subjects were assigned the LMC masks and Group 2 subjects were assigned conventional masks. The PEF and FENO were obtained from Group 1 and Group 2 prior to wearing the assigned mask. Group 1 (n=34) had a mean PEF of 430.3±85.2 L/min and FENO of 13.2±6.5 ppb. Group 2 (n=33) had a mean PEF of 433±99.1 L/min and FENO of 11.8±7.0. Comparison of PEF (p>0.05) and FENO (p>0.05) between Group 1 and Group 2 demonstrated no significant difference (Figure 2 A,B).
Table 1.

Demographic and functional characteristics of study subjects.

Subject characteristics (n=67)Mean±SD or % (n)
Demographic characteristics
    Age, years39.4±10.2
    Male (female), %32.8 (67.2)
    Height, cm159.6±6.9
    Weight, kg56.8±7.7
    BMI, kg/m226.4±2.9
Job title
    Administrative staff, % (n)14.9 (10/67)
    Teacher, % (n)65.7 (44/67)
    Other, % (n)19.4 (13/67)
Comorbidity
    High blood pressure, % (n)2.9 (2/67)
    Arrhythmia or coronary disease, % (n)1.5 (1/67)
    Diabetes, % (n)2.9 (2/67)
    Rheumatology, % (n)2.9 (2/67)
    Non, % (n)89.8 (60/67)
Functional characteristics
    PEF, L/min431.7±92.2
    FENO, ppb12.5±6.8
    Mask wearing time, hours2.5±0.5

BMI, body mass index; PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion.

Table 2.

Characteristics of study subjects defined by Group 1 and Group 2.

Characteristics of research subjectsGroup 1 (N=34)Group 2 (N=33)p
Demographic characteristics
    Age, years38.7±9.740.1±10,.NS
    Male (female), %32.8 (67.2)36.3 (63.7)NS
    Height, cm160.1±6.3159±7.5NS
    Weight, kg56.7±7.357.0±8.1NS
    BMI, kg/m225.6±2.827.0±2.8NS
Job title
    Administrative staff, % (n)14.7(5)15.2(5)NS
    Teacher, % (n)64.7(22)66.7(22)NS
    Other, % (n)20.6(7)18.1(6)NS
Comorbidity
    High blood pressure, % (N)2.9(1)3.0(1)NS
    Arrhythmia or coronary disease, % (N)2.9(1)3.0(1)NS
    Diabetes, % (N)2.9(1)0.0 (0)NS
    Rheumatology, % (N)2.9(1)3.0(1)NS
    Non, % (N)88.491.0NS
Functional characteristics
    Peak flow, L/min430.3±85.2433±99.1NS
    FENO, ppb13.2±6.511.8±7.0NS
    Mask wearing time, hours2.8±0.22.8±0.1NS

BMI, body mass index; PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion. Group 1, LMC mask use; Group 2, conventional mask use.

Figure 2.

Comparison of PEF and FENO between Group 1 and Group 2 before mask use. PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion; Group 1, LMC mask use; Group 2, conventional mask use.

Demographic and functional characteristics of study subjects. BMI, body mass index; PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion.

Modification of PEF and FENO after mask use in each Group and between Group 1 and Group 2

The results (Figures 2 and 3, Table 3) showed that there was no significant difference of PEF between before and after mask use for Group 1 and Group 2 (430.3±85.2 vs 435.5±76.9 L/min and 433±99.1 vs 428.2±104.6 L/min, respectively; Table 3). In Group 1, the level of FENO after mask use was lower than that measured before mask use (8.2±4.2 vs 13.2±6.5, p=0.01; Table 3). The level of FENO in Group 2 after mask use was higher than that measured before mask use (12.3±7.4 vs 11.8±7.0 ppb; Table 3) but there was no significant difference (p>0.05).
Figure 3.

Comparison of PEF and FENO between Group 1 and Group 2 after mask use. PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion; Group 1, LMC mask use; Group 2, conventional mask use.

Table 3.

Comparison of modifications of PEF and FENO after mask use between Group 1 and 2.

ParametersBefore mask useAfter mask usep
Peak flow (L/min)
    Group 1 (n=34)430.3±85.2435.5±76.9NS
    Group 2 (n=33)433±99.1428.2±104.6NS
FENO (ppb)
    Group 1 (n=34)13.2±6.58.2±4.20.01
    Group 2 (n=33)11.8±7.012.3±7.4NS

PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion. Group 1, LMC mask use; Group 2, conventional mask use.

Comparison of PEF and FENO between Group 1 and Group 2 before mask use. PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion; Group 1, LMC mask use; Group 2, conventional mask use. Characteristics of study subjects defined by Group 1 and Group 2. BMI, body mass index; PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion. Group 1, LMC mask use; Group 2, conventional mask use. The PEF and FENO were obtained from group Group 1 (LMC masks) and Group 2 (conventional masks) after wearing assigned masks for three hours (Figure 3 A,B). Group 1 (n=34) had a mean PEF of 435.5±76.9 L/min and FENO of 8.2±4.2 ppb. Group 2 (N= 33) had a mean PEF of 428.2±104.6 L/min and FENO of 12.3±7.4 ppb. Comparison of FENO between Group 1 and Group 2 demonstrated a statistical significance of FENO (p<0.05) but not of PEF (p>0.05) (Figure 3 A,B).

Comparison of subjective symptoms of study subjects after mask use

Subjective symptoms reporting after wearing the mask found that the LDC mask was more comfortable to wear. In Group 1, study subjects who wore the LMC mask, 79.4% reported the beneficial effect with clearer nasal passageways. For those who wore the conventional mask (Group 2), 6.1% reported clearer nasal passageways (Table 4). In Group 1, 8.8% reported sneezing or stuffy nose and 2.9% reported itchy throat (Table 4). In Group 2, 15.2% reported sneezing, stuffy nose or runny nose; 6.1% in Group 2 reported sore throat, 15.1% reported cough after wearing conventional mask and 3.0% reported difficulty breathing (Table 4 and Figure 4). There was a significant difference between Group 1 and Group 2 for respiratory and throat symptoms after mask use (p<0.05 and p<0.05, respectively; Table 4 and Figure 4).
Table 4.

Comparison of subjective symptoms of study subjects after mask use.

ParametersGroup 1 (n=34)Group 2 (n=33)p
Normal, %38.2(13)48.4(16)NS
Favorable effect
Clearer nasal passageways, %79.4(27)6.1(2)<0.0001
Side effect
Nasal symptoms, %8.8(3)15.2(5)NS
    Sneezing, %5.9(2)6.1(2)NS
    Stuffy nose, %2.9(1)6.1(2)NS
    Runny nose, %0.0 (0)3.0(1)NS
Throat symptoms, %2.9(1)18.2(6)0.020
    Itchy throat, %2.9(1)12.1(4)NS
    Sore throat, %0.0 (0)6.1(2)NS
Respiratory symptoms, %2.9(1)18.2(6)0.020
    Cough, %2.9(1)15.2(5)0.009
    Difficulty breathing, %0.0 (0)3.0(1)NS

Group 1, LMC mask use; Group 2, conventional mask use.

Figure 4.

Comparison of subjective symptoms of study subjects after mask use.

Comparison of modifications of PEF and FENO after mask use between Group 1 and 2. PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion. Group 1, LMC mask use; Group 2, conventional mask use. Comparison of PEF and FENO between Group 1 and Group 2 after mask use. PEF, peak expiratory flow; FENO, fractional concentration of nitric oxide in exhaled breath; ppb, part per billion; Group 1, LMC mask use; Group 2, conventional mask use. Comparison of subjective symptoms of study subjects after mask use. To confirm the sterilization of brand new masks (LMC and conventional masks), five new masks in each Group were chosen randomly for bacterial culture. The results showed clear (sterile) rings for both masks (100%; n=5) with no significant difference of mean radius (1.0±0.2 vs 0.8±0.3 cm, respectively; p>0.05), confirming both masks were resistant to bacteria. For aerobic microbial testing, on the disc implant of the mask of Group 1, there appeared a sterile ring with a radius of 0.5±0.2 cm in 100% mask cultured pieces (n=15). On the mask of Group 2, there appeared bacteria in 100% of mask cultured pieces (not identified; n=15). Antibacterial ability of masks of Group 1 appears better than Group 2, suggesting improved aerobic bacterial resistance in the LMC mask.

Discussion

This study suggests that the LMC face mask is equal in effectiveness and perhaps superior compared to internationally sold surgical face masks. Furthermore, the study demonstrates that utilizing local resources to manufacture face masks may be a feasible alternative to purchasing international face masks, especially during a COVID-19 pandemic when resources are scarce. Oil from Folium Plectranthii amboinicii (Lour.) Speng was found to be an effective antimicrobial when tested and it may be an effective addition to the production of face masks. Furthermore, the decrease in FENO (Figure 3) demonstrated that the antimicrobial component of LMC mask including extracts from Folium Plectranthii amboinicii (Lour.) Speng, activated carbon and BSI solution did not produce the bronchial allergic response that usually is manifested by increased FENO and might be due to the improvement of comfortability with breathing (Table 4 and Figure 4). However, the levels of FENO before and after the use of LMC masks were still in normal range. In this study, FENO was used to evaluate the effect of active carbon associated with BSI solution and Folium Plectranthii amboinicii (Lour.) Speng oil extract on the airways. Interestingly, the level of FENO after LMC mask use was significantly lower than that measured before LMC mask use (Table 3). This result suggests LMC mask do not have an allergic effect on the airways of users because this effect usually increase FENO level. The positive results of subjective comfortability also demonstrated the beneficial effects of LMC mask use that might explain another possible reason for the drop in FENO after mask using would be the good breathing during mask wearing; thus, with our LMC mask, comfort was greater and tolerance better suggesting that hyperventilation unlikely accounted for the drop in FENO. Face masks are an integral component of infection prevention in the healthcare setting. The effectiveness of a mask in preventing inhalation of pollutants and pathogens is dependent on the intrinsic ability of the mask to withstand penetration of airborne particles [16]. N95 respirators have a filtering capacity of at least 95% of the challenge aerosol, whereas conventional masks have a filtering capacity of 10% to less than 90% [17-19]. The manufactured mask of this study (LMC face mask), made of 5 layers of heat seal filter paper, combined with two blotting paper in the medium which have been covered by activated carbon, BSI solution and Folium Plectranthii amboinicii oil extract, has a high performance of filter capacity after seal heating, and can be used to replace traditional surgical masks, but more data are necessary before it can replace N95 or greater masks. However, N95 and greater masks that are not properly fitted and do not seal, do not have the same efficacy compared to fitted masks that form a seal making proper fitting an integral part of using N95 masks [3]. Without proper fitting they may not be any more effective than LMC mask. In the present study, the LMC face mask was found to have reduced upper airway symptoms and irritation, and may be a more comfortable alternative to conventional face masks. The subjective reporting of reduced upper airway symptoms and irritation is supported by FENO measurement after use, a biomarker of airway inflammation and hyper-reactivity [13]. The FENO of subjects wearing the LMC face mask was improved in comparison to those wearing the conventional face mask but the levels of FENO in both groups of study subjects were still in normal range for adults (Table 3 and Figure 3). The drop of FENO after using LMC masks suggests that the paper masks with oil from Plectranthii amboinicii may be more comfortable for people to wear the face mask. FENO has been known as a biomarker of airway inflammation and used in diagnosis of airway hypersensitivity, mainly in asthma [13,20]. The normal level of FENO measured after wearing the LMC mask suggests that LMC mask did not have any allergic or inflammatory effect on the airways due to the use of mask. In addition, this study found that the LMC face mask may have equal filtering capacity to internationally sold conventional surgical and medical masks. A recent study on homemade face masks demonstrated that conventional surgical and medical masks were three times more effective in reducing microorganism transmission compared to homemade masks [21]. The current study suggests that the LMC face mask may be equal in effectiveness to preventing airborne infections when compared to conventional masks. In fact, our previous studies demonstrated that oil extracted from Folium Plectranthii amboinicii (Lour.) Speng has antimicrobial and anti-inflammatory activity. The present study utilized the antimicrobial capacity of the oil from Plectranthii amboinicii and showed reduced bacterial and fungal growth on the LMC mask compared to the conventional mask. The LMC mask appears to have equal filtering capacity to conventional masks, but also has an improved antibacterial one secondary to the oil from Folium Plectranthii amboinicii (Lour.) Speng. Comparison of subjective symptoms of study subjects after mask use. Group 1, LMC mask use; Group 2, conventional mask use. Because the LMC face mask was manufactured using local available materials, the study implies that in the setting of a COVID-19 pandemic, healthcare material suppliers could manufacture their own face masks using locally sourced materials [22]. This would improve the supply of medical masks in the community during a shortage of mask due to COVID-19 pandemic. Seal heat filter paper and other locally sourced materials, rather than plastic, were used to manufacture the LMC face mask. The reduced reliance on plastic is more sustainable and cleaner for the environment, making it easier for individual countries to maintain an adequate supply of safe and renewable face masks during future pandemic. The patent requirement of LMC face mask has been submitted at National Office of Intellectual Property of Vietnam in March 2020. The study does have some limitations. Subjects were recruited only from staff of local college. Thus, the results may not be generalizable to the general public and other demographic groups. Subjects were not exposed to pathogens while wearing the masks. Therefore, it is possible we may be overestimating the effectiveness of the mask. In addition, subjects were asked to provide binary answers to subjective questions on comfort and breathability while wearing the mask. Lastly, long term safety from inhalation exposure to the plant oil, such as lipoid pneumonia, cannot be excluded, but none of the recruited subjects demonstrated signs or symptoms from the use of the mask over the following weeks. Nonetheless, our results suggest using high quality of filter paper to make masks during the pandemic-induced mask shortage can be successful. LMC mask provided easier breathability, less airway inflammation demonstrated by improved FENO values, and equal efficacy as conventional masks. Despite the challenges, further investigation with a greater number of subjects should be performed to determine if oil from Folium Plectranthii amboinicii (Lour.) Speng can improve the function and breathability of face masks and be worn without any ill effects for extended periods of time.

Conclusions

Creating a medical face mask utilizing locally sourced materials as well as adding oil from Folium Plectranthii amboinicii (Lour.) Speng to improve antimicrobial capacity and breathability of the mask is possible. However, the study could not assess whether the LMC mask provides extended protection from pathogens, especially viral pathogens, as compared to N95, but appears to be ample in efficacy as traditionally used medical and surgical masks. Nonetheless, the study shows that face masks can be locally manufactured during an epidemic with a cleaner impact on the environment compared to conventional plastic-based face masks. Further research should be undertaken to determine if the addition of oil from Folium Plectranthii amboinicii (Lour.) Speng provides additional antimicrobial protection to conventional face masks.
  16 in total

1.  An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications.

Authors:  Raed A Dweik; Peter B Boggs; Serpil C Erzurum; Charles G Irvin; Margaret W Leigh; Jon O Lundberg; Anna-Carin Olin; Alan L Plummer; D Robin Taylor
Journal:  Am J Respir Crit Care Med       Date:  2011-09-01       Impact factor: 21.405

2.  Low Variability in Peak Expiratory Flow Predicts Successful Inhaled Corticosteroid Step-Down in Adults with Asthma.

Authors:  Naomi Tsurikisawa; Chiyako Oshikata; Toshio Sato; Goro Kimura; Masami Mizuki; Takahiro Tsuburai; Shunsuke Shoji; Hiroshi Saito; Terufumi Shimoda
Journal:  J Allergy Clin Immunol Pract       Date:  2017-12-06

3.  Challenges to the system of reserve medical supplies for public health emergencies: reflections on the outbreak of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epidemic in China.

Authors:  Xu Wang; Xiaoxi Zhang; Jiangjiang He
Journal:  Biosci Trends       Date:  2020-02-17       Impact factor: 2.400

Review 4.  Effectiveness of N95 respirators versus surgical masks in protecting health care workers from acute respiratory infection: a systematic review and meta-analysis.

Authors:  Jeffrey D Smith; Colin C MacDougall; Jennie Johnstone; Ray A Copes; Brian Schwartz; Gary E Garber
Journal:  CMAJ       Date:  2016-03-07       Impact factor: 8.262

5.  Study of the beneficial role of exhaled nitric oxide in combination with GINA guidelines for titration of inhaled corticosteroids in children with asthma.

Authors:  H Dinh-Thi-Dieu; A Vo-Thi-Kim; H Tran-Van; T Tang-Thi-Thao; S Duong-Quy
Journal:  J Breath Res       Date:  2020-03-27       Impact factor: 3.262

6.  Potential demand for respirators and surgical masks during a hypothetical influenza pandemic in the United States.

Authors:  Cristina Carias; Gabriel Rainisch; Manjunath Shankar; Bishwa B Adhikari; David L Swerdlow; William A Bower; Satish K Pillai; Martin I Meltzer; Lisa M Koonin
Journal:  Clin Infect Dis       Date:  2015-05-01       Impact factor: 9.079

7.  Performance of an N95 filtering facepiece particulate respirator and a surgical mask during human breathing: two pathways for particle penetration.

Authors:  Sergey A Grinshpun; Hiroki Haruta; Robert M Eninger; Tiina Reponen; Roy T McKay; Shu-An Lee
Journal:  J Occup Environ Hyg       Date:  2009-10       Impact factor: 2.155

8.  Study of the Interference between Plectranthus Species Essential Oils from Brazil and Aminoglycosides.

Authors:  Fabíola Fernandes Galvão Rodrigues; José Galberto Martins Costa; Fábio Fernandes Galvao Rodrigues; Adriana Rolim Campos
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-04       Impact factor: 2.629

9.  Filter performance of n99 and n95 facepiece respirators against viruses and ultrafine particles.

Authors:  Robert M Eninger; Takeshi Honda; Atin Adhikari; Helvi Heinonen-Tanski; Tiina Reponen; Sergey A Grinshpun
Journal:  Ann Occup Hyg       Date:  2008-05-13

10.  Fractional Exhaled Nitric Oxide (FENO) in the management of asthma: a position paper of the Italian Respiratory Society (SIP/IRS) and Italian Society of Allergy, Asthma and Clinical Immunology (SIAAIC).

Authors:  Enrico Heffler; Giovanna Elisiana Carpagnano; Elisabetta Favero; Giuseppe Guida; Mauro Maniscalco; Andrea Motta; Giovanni Paoletti; Giovanni Rolla; Eugenio Baraldi; Vincenza Pezzella; Giorgio Piacentini; Stefano Nardini
Journal:  Multidiscip Respir Med       Date:  2020-02-19
View more
  2 in total

1.  Interleukin-6 blocking agents for treating COVID-19: a living systematic review.

Authors:  Lina Ghosn; Anna Chaimani; Theodoros Evrenoglou; Mauricia Davidson; Carolina Graña; Christine Schmucker; Claudia Bollig; Nicholas Henschke; Yanina Sguassero; Camilla Hansen Nejstgaard; Sonia Menon; Thu Van Nguyen; Gabriel Ferrand; Philipp Kapp; Carolina Riveros; Camila Ávila; Declan Devane; Joerg J Meerpohl; Gabriel Rada; Asbjørn Hróbjartsson; Giacomo Grasselli; David Tovey; Philippe Ravaud; Isabelle Boutron
Journal:  Cochrane Database Syst Rev       Date:  2021-03-18

Review 2.  A comprehensive review on antimicrobial face masks: an emerging weapon in fighting pandemics.

Authors:  Gayathri Pullangott; Uthradevi Kannan; Gayathri S; Degala Venkata Kiran; Shihabudheen M Maliyekkal
Journal:  RSC Adv       Date:  2021-02-08       Impact factor: 3.361

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.